poisar

Stocks · News reference

Foghorn Therapeutics shares are trading lower after the company and Lilly decided not to advance FHD-909 into the expansion phase and discontinued their SMARCA2 degrader collaboration.

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading